|
|||||
|
|
Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease |
|
| Authors: | Selby Warwick Pavli Paul Crotty Brendan Florin Tim Radford-Smith Graham Gibson Peter Mitchell Brent Connell William Read Robert Merrett Michael Ee Hooi Hetzel David;Antibiotics in Crohn's Disease Study Group |
| Institution: | Royal Prince Alfred Hospital, Sydney, Australia. warwicks@mail.med.usyd.edu.au |
| Abstract: | BACKGROUND & AIMS: Mycobacterium avium subspecies paratuberculosis has been proposed as a cause of Crohn's disease. We report a prospective, parallel, placebo-controlled, double-blind, randomized trial of 2 years of clarithromycin, rifabutin, and clofazimine in active Crohn's disease, with a further year of follow-up. METHODS: Two hundred thirteen patients were randomized to clarithromycin 750 mg/day, rifabutin 450 mg/day, clofazimine 50 mg/day or placebo, in addition to a 16-week tapering course of prednisolone. Those in remission (Crohn's Disease Activity Index |
| Keywords: | CDEIS Crohn’s Disease Endoscopic Index of Severity MAP Mycobacterium avium subspecies paratuberculosis MP mercaptopurine |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ | |